| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H38O |
| Molecular Weight | 330.5472 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 3 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C
InChI
InChIKey=HUCXKZBETONXFO-NJFMWZAGSA-N
InChI=1S/C23H38O/c1-19(2)11-7-12-20(3)13-8-14-21(4)15-9-16-22(5)17-10-18-23(6)24/h11,13,15,17H,7-10,12,14,16,18H2,1-6H3/b20-13+,21-15+,22-17+
| Molecular Formula | C23H38O |
| Molecular Weight | 330.5472 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 3 |
| Optical Activity | NONE |
Tetraprenylacetone (Geranylgeranylacetone) is an anti-peptic ulcer drug developed and approved in Japan in 1984. Tetraprenylacetone is shown to suppress H. pylori induced tissue and cell injury and inflammatory reaction, so it is expected to show beneficial effects on H. pylori-infected tissues. Tetraprenylacetone is used to treat patients suffering from peptic ulcers and gastritis. In Japan it is sold under the brand name Selbex.
CNS Activity
Originator
Approval Year
Doses
AEs
PubMed
Patents
Sample Use Guides
Capsules 50 mg:
The usual adult dosage for oral use is 3 capsules (150 mg
of teprenone) daily in three divided doses after meals.
The dosage may be adjusted depending on the patient’s
age and symptoms.
Fine Granules 10%:
The usual adult dosage for oral use is 1.5 g (150 mg of
teprenone) daily in three divided doses after meals. The
dosage may be adjusted depending on the patient’s age
and symptoms.
Route of Administration:
Oral